Business

SNT: Recurring revenue and radio-pharmaceutical sales rose, while EBITDA margin improved

SNT: Recurring revenue and radio-pharmaceutical sales rose, while EBITDA margin improved

Synektik SaFebruary 5, 20254
SNT: Recurring revenue and radio-pharmaceutical sales rose, while EBITDA margin improved

About this update from Synektik Sa

Revenue and net profit declined year-over-year, but recurring revenues and radio-pharmaceutical sales grew strongly. EBITDA margin improved, and the group expanded its product portfolio and geographic reach, including new exclusive distribution agreements and an IT acquisition.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Synektik Sa